Mitochondrial Polypeptide Biomarkers for Early Ischemia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac markers fail to accurately detect myocardial ischemia before cell death occurs, limiting early treatment options for patients with acute coronary syndromes and hindering prognosis improvement.
Innovation Solution
The method involves detecting mitochondrial polypeptides, such as N-formyl polypeptides or Nourin-1, in bodily samples to diagnose cardiac damage and ischemia, as these peptides are released during mitochondrial disruption due to cardiac injury, allowing for earlier detection of ischemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cardiac markers (troponin, CK-MB, myoglobin) are used, then diagnosis of myocardial infarction can be made, but detection of myocardial ischemia before cell death cannot be achieved
Solution Approach 1:
The patent extracts and measures mitochondrial proteins specifically from the intermembrane space (such as cytochrome c, Hsp60, and Hsp70) as separate biomarkers. By focusing on this specific mitochondrial compartment rather than general cardiac markers, the invention enables detection of ischemia at an earlier stage before cell death occurs, thus resolving the contradiction between detection accuracy and timing.
2Reliability
If traditional risk factors (cholesterol, blood pressure) are monitored, then some cardiovascular risk can be identified, but accurate detection of acute ischemia is not achieved
Solution Approach 1:
The patent introduces mitochondrial proteins as intermediary biomarkers that bridge the gap between traditional risk factors and direct cell death markers. These mitochondrial proteins serve as mediators that indicate ischemic stress before irreversible damage occurs, providing a reliable detection mechanism without requiring complex panels of multiple traditional markers.
3Productivity
If observation and monitoring are extended to detect early ischemia, then early treatment decisions can be made, but clinical utility is limited without specific markers
Solution Approach 1:
The patent enables preliminary detection of myocardial ischemia by measuring mitochondrial proteins before cell death occurs. This preliminary action provides critical information about the early ischemic stage, allowing clinicians to make treatment decisions before irreversible damage happens, thus maximizing clinical utility and preventing loss of diagnostic information.
Data Source
AI summary
Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.